Propanc Biopharma Announces Fiscal Year-End Highlights and Digital Asset Treasury Strategy

Propanc Biopharma reported a significant increase in total assets and stockholders' equity to $19.6 million and $13.9 million, respectively, driven by prepaid service contracts. The company completed an IPO and uplisting to Nasdaq, generating $4 million in gross proceeds. Propanc plans to advance its lead therapeutic candidate, build its IP portfolio, and create a $100 million+ digital asset treasury over the next 12 months.